

MOST URGENT



**NO. SO(RMC)2-21/2025
GOVERNMENT OF THE PUNJAB
SPECIALIZED HEALTHCARE &
MEDICAL EDUCATION DEPARTMENT
(TECHNICAL WING)**

Dated Lahore, the 6th January, 2026

To

1. Vice Chancellors of all public sector Medical Universities in Punjab
2. Principals / Deans / EDs of all public sector Medical Colleges / Specialized Medical Institutions in Punjab
3. Medical Superintendents of all public sector Teaching Hospitals in Punjab

**Subject: DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL
DRUG TESTING LABORATORIES.**

I am directed to refer the subject cited above and to enclose herewith copy of a letters No. 13-30/2024-DD(QA-VIII) dated 18.12.2025 received from the Deputy Director-IX (QA & LT), Drug Regulatory Authority of Pakistan, Division of Quality Assurance & Laboratory Testing, Prime Minister's National Health Complex, Islamabad.

2. Submitted for information and further necessary action.

SECTION OFFICER (RMC)

NO & DATE EVEN:

Copy is forwarded for information to the:

1. Deputy Director-IX (QA & LT), Drug Regulatory Authority of Pakistan, Division of Quality Assurance & Laboratory Testing, Prime Minister's National Health Complex, Islamabad w/r to letter referred above.
2. PSO to Secretary to Government of the Punjab, Specialized Healthcare & Medical Education Department.
3. PS to Special Secretary (Operations), Specialized Healthcare & Medical Education Department.
4. P.A. to Additional Secretary (Technical), Specialized Healthcare & Medical Education Department.

SECTION OFFICER (RMC)

MOST URGENT



13-30/2024-DD(QA-VIII)
Government of Pakistan
Drug Regulatory Authority of Pakistan
Division of Quality Assurance & Laboratory Testing
Prime Minister's National Health Complex, Islamabad.

25
MOST IMMEDIATE

Islamabad, the 18th December, 2025.

Subject: **DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG TESTING LABORATORIES.**

I am directed to refer to the subject cited above and report received from DTLs Punjab wherein below mentioned Drug Products declared 'Substandard' quality. Details of products are as under:

S#	Product Name	Batch No.	Manufacturers	Remarks
1.	Tablet Ascard 75 mg Each Enteric Coated Tablet Contains: Acetylsalicylic Acid (Aspirin BP)75mg (Reg. # 016600)	AR034L	M/s Atco Laboratories Limited, B-18 S.I.T.E Karachi. (DML # 000537)	The sample is declared as "sub-standard" on the basis of Test for Related Substances (Impurity C: Salicylic Acid).
2.	Sachet PREVASMA Each Sachet Contains: Montelukast Sodium USP eq. to Montelukast 4.0 mg (Reg. # 074838)	033	M/s MKB Pharmaceuticals (Pvt) Ltd. 66-Hayatabad Industrial Estate Jamrud Road Peshawar. (DML # 000617)	The sample is declared as "sub-standard" on the basis of Test for Impurities i.e. Organic Impurities.

2. The above mentioned firm is hereby directed to immediately alert your sales officers/suppliers/distributors to issue instructions to the distributors, for the return of suspected stocks of the above mentioned batch of the product & within three working (03) days, you are directed to submit 'Recall Assessment Form to this division in light of guidance provided in the "Guidelines on Recall of Defective Therapeutic Goods (Edition 02)" available on DRAP's website i.e. <https://www.dra.gov.pk/wp-content/uploads/2024/11/Recall-Guidelines-Edition-2-V1-1-Final-08-10-2024-1-2.pdf>.

(SALATEEN WASEEM PHILIP)
Deputy Director-IX (QA<)

Copy for information and necessary action - with request to issue necessary directions to points of use/sale under administrative control/ fall under area of jurisdiction to ensure recall of defective product from the market, please.

1. The Secretary (SHC&ME) Health Department (Government of Punjab).
2. The Secretary Population Welfare Department (Government of Punjab).
3. The Secretary Health Department (Government of Sindh).
4. The Secretary Health Department (Government of KP).
5. The Secretary Health Department (Government of Baluchistan).
6. The Secretary, Health Department (Government of AJ&K).
7. The Secretary, Health Department (Government of Gilgit Baltistan).
8. The Additional Director / Office In-charge, DRAP, Lahore, Karachi, Islamabad, Peshawar, and Faisalabad.
9. The Chief Drug Controller / Inspector Punjab, Sindh, Khyber Pakhtunkhwa, Baluchistan, AJ&K, Gilgit Baltistan, and Islamabad Capital Territory.

Copy to:-

- i. Area FID, to coordinate with concerned manufacturer regarding oversight of the recall process and also investigate as per para 5 of this letter within the required time.
- ii. Office copy

Special Secretary (D&R)	
Diary No. _____	
Date: 24-12	
AS (D)	AS (F)
AS (P)	AS (ME)
CPO	GM&PU
AS	DS

SECRETARY SHC&ME	
Diary No. 12159	
Date: 24/12/25	
SS (OPS)	SS (D&R)
ASA	ASD
ASE	ASF
AST	ASP
DS ()	CPO

Diary No. _____
Date: 30.12.25
SO (RMC)
SO (PHP)
SO (OPs)
SO (ABs) [OT with request to oversight]
SO (TECH)

PA to A.S (PROCUREMENT)	
FUC No. _____	
Date: 28/12/25	
SO (P-I)	SO (P-II)
SO (P-III)	SO (P-IV)
SO (P-V)	SO (P-VI)

Deputy Director - IX (QA<)

Page 1 of 1

DS (Proc) SHC&ME Deptt.

Diary No. 6533

Date: 29/12/25